Lapatinib (GW-572016) Ditosylate

Catalog No.S1028

Lapatinib (GW-572016) Ditosylate Chemical Structure

Molecular Weight(MW): 925.46

Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 400 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 54 Publications

7 Customer Reviews

  • Combination of NVP-AEW541 and lapatinib cooperatively inhibits the growth of NVP-AEW541 resistant murine rhabdomyosarcoma primary cell cultures with Igf1r/Her2 complexes. Cell viability assay for Naïve, untreated (U20325; A) and NVP-AEW541 innately resistant mouse rhabdomyosarcoma primary culture (U44676; B) treated with varying concentrations of NVP-AEW541, lapatinib, or a combination of both. Naïve cells (U20325) were sensitive to NVP-AEW541, but lapatinib had no cooperativity. In contrast, NVP-AEW541 at moderate doses increased cell growth in resistant cell cultures (U44676). However, this paradoxical effect was reduced by the addition of lapatinib, although lapatinib treatment alone had very little effect. C, the NVP-AEW541 resistant primary tumor cell line (U44676) was treated with DMSO, 5 μmol/L lapatinib, 5 μmol/L NVP-AEW541, and a combination of 5 μmol/L NVP-AEW541+lapatinib for 25 minutes and Western blot analysis was done on lysates for p-Igf1r and p-Her2.

    Mol Cancer Ther 2011 10:697-707. Lapatinib (GW-572016) Ditosylate purchased from Selleck.

    (B-C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 lg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955 . Lapatinib (GW-572016) Ditosylate purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Lapatinib (GW-572016) Ditosylate purchased from Selleck.

    Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean   standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Lapatinib (GW-572016) Ditosylate purchased from Selleck.

  • Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May-Gruenwald-Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Lapatinib (GW-572016) Ditosylate purchased from Selleck.

    Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Lapatinib (GW-572016) Ditosylate purchased from Selleck.

  • After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of Lapatinib for 3h,followed by 20-minute  stimolation of 100ng/ml EGF.

     

     

    Dr. Zhang of Tianjin Medical University. Lapatinib (GW-572016) Ditosylate purchased from Selleck.

Purity & Quality Control

Choose Selective HER2 Inhibitors

Biological Activity

Description Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
Targets
ErbB2 [1]
(Cell-free assay)
EGFR [1]
(Cell-free assay)
ErbB4 [1]
(Cell-free assay)
9.2 nM 10.8 nM 367 nM
In vitro

Lapatinib Ditosylate weakly inhibits the activity of ErbB4 with IC50 of 367 nM, and displays >300-fold selectivity for EGFR and ErbB2 over other kinases such as c-Src, c-Raf, MEK, ERK, c-Fms, CDK1, CDK2, p38, Tie-2, and VEGFR2. Lapatinib Ditosylate significantly inhibits receptor autophosphorylation of EGFR and ErbB2 in a dose-dependent manner with IC50 of 170 nM and 80 nM, respectively in HN5 cells; as well as 210 nM and 60 nM, respectively in BT474 cells. Unlike OSI-774 and Iressa (ZD1839) which preferentially inhibit the growth of the EGFR-overexpressing cells, Lapatinib Ditosylate inhibits the growth of both EGFR- and ErbB2-overexpressing cells. Lapatinib Ditosylate displays higher inhibitory activity against EGFR- or ErbB2-overexpressing cells with IC50 of 0.09-0.21 μM, compared with cells expressing low levels of EGFR or ErbB2 with IC50 of 3-12 μM, and exhibits ~100-fold selectivity over the normal fibroblast cells. Lapatinib Ditosylate potently inhibits the outgrowth of EGFR-overexpressing HN5 and A-431 cells, as well as ErbB2-overexpressing BT474 and N87 cells, and significantly induces G1 arrest of HN5 cells and apoptosis of BT474 cells, which are associated with inhibition of AKT phosphorylation. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HN5 cell line M4jkdnBzd2yrZnXyZZRqd25iYYPzZZk> MVjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiQNTDj[YxtKGyrbnWsJGlEPTB;MD6wNlUh|ryP MUixOlQ5Ozd5Mh?=
BT474 cell line MoqwVJJwdGmoZYLheIlwdiCjc4PhfS=> M4HDdWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQmS0O|Qh[2WubDDsbY5mNCCLQ{WwQVAvODJ3IN88US=> NFrheVYyPjR6M{e3Ni=>
HN5 cell NXfMPZZQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVTBW495UW6qaXLpeIlwdiCxZjDIUlUh[2WubDDndo94fGhiYX\0[ZIhPzJiaILzMEBKSzVyPUCuNVIh|ryP NH:1Z|cyPjd5N{SxNC=>
BT474 cell Mlq0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3q0Z2lvcGmkaYTpc44hd2ZiQmS0O|Qh[2WubDDndo94fGhiYX\0[ZIhPzJiaILzMEBKSzVyPUCuNFgh|ryP NULpUVdFOTZ5N{e0NVA>
N87 cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXLrU5VbUW6qaXLpeIlwdiCxZjDOPFch[2WubDDndo94fGhiYX\0[ZIhPzJiaILzMEBKSzVyPUCuNFgh|ryP MWSxOlc4PzRzMB?=
HFF cell MlvsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWDxeHkzUW6qaXLpeIlwdiCxZjDISmYh[2WubDDndo94fGhuIFnDOVA:QS57IN88US=> MXWxOlc4PzRzMB?=
SKBR3 cells M{nDNmN6fG:2b4jpZ4l1gSCjc4PhfS=> MnvPR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tDWjNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlAyPyEQvF2= NF;YXYIyQTB{OESyOS=>
A431 cells M3[xU2N6fG:2b4jpZ4l1gSCjc4PhfS=> NXTPZ40{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTR|MTDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOTB2IN88US=> MXqxPVg5QDd4MR?=
SKBR3 cells MnL4R5l1d3SxeHnjbZR6KGG|c3H5 MY\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT2JTOyClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuNFI6KM7:TR?= MUexPVg5QDd4MR?=
HepG2 cells NYLZZWJxWHKxbHnm[ZJifGmxbjDhd5NigQ>? M37YW2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS|Ih[2WubIOgZYZ1\XJiaILzJIJ6KEGWUDDjc451\W62IHHzd4F6NCCLQ{WwQVYvOjdizszN NFrkfVIzODF2M{e3PC=>
Hep3B2 cells M3PPUnBzd2yrZnXyZZRqd25iYYPzZZk> NIf2clZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldFNDOiClZXzsd{Bi\nSncjDodpMh[nliQWTQJINwdnSnboSgZZN{[XluIFnDOVA:PS52OTFOwG0> NH\vOGgzODF2M{e3PC=>
SKHEP1 cells NX\5bZN7WHKxbHnm[ZJifGmxbjDhd5NigQ>? MkTsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVS1jFVFEh[2WubIOgZYZ1\XJiaILzJIJ6KEGWUDDjc451\W62IHHzd4F6NCCLQ{WwQVUvOyEQvF2= MWKyNFE1Ozd5OB?=
MCF7 cells NI\iRmVRem:uaX\ldoF1cW:wIHHzd4F6 NIT0TFdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiaILzJIJ6KEGWUDDjc451\W62IHHzd4F6NCCLQ{WwQVYvPiEQvF2= NUTQbI84OjBzNEO3O|g>
MDA-MB-231 cells NH;HeXVRem:uaX\ldoF1cW:wIHHzd4F6 MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[W[2ZYKgbJJ{KGK7IFHUVEBkd262ZX70JIF{e2G7LDDJR|UxRTVwNDFOwG0> MYWyNFE1Ozd5OB?=
SK-BR-3 cells MnfEVJJwdGmoZYLheIlwdiCjc4PhfS=> M1z3ZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utRnIuOyClZXzsd{Bi\nSncjDodpMh[nliQWTQJINwdnSnboSgZZN{[XluIFnDOVA:OC5yNDFOwG0> MYSyNFE1Ozd5OB?=
A431 cells Mkn2SpVv[3Srb36gZZN{[Xl? MWTJcohq[mm2aX;uJI9nKEWJRmKgbY51emGlZXzseYxieiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hSTR|MTDj[YxteyCkeTDFUGlUSSxiSVO1NF0xNjB3MjFOwG0> NGGxcXAzODN2Nk[1OS=>
N87 cells NIK4U4xHfW6ldHnvckBie3OjeR?= M2TW[GlvcGmkaYTpc44hd2ZiRYLiRlIhcW62cnHj[YxtfWyjcjDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iTki3JINmdGy|IHL5JGVNUVODLDDJR|UxRTBwMTFOwG0> NXT2O414OjB|NE[2OVU>
MIAPaCa cells Mo\DSpVv[3Srb36gZZN{[Xl? M3XBV2lvcGmkaYTpc44hd2ZiRVfGVkBxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gUWlCWGGFYTDj[YxteyCkeTDFUGlUSSxiSVO1NF0xNjR|MzFOwG0> NE\lSXozODhzN{WyNy=>
MIAPaCa cells MX;GeY5kfGmxbjDhd5NigQ>? MWfJcohq[mm2aX;uJI9nKEWUQnKyJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDNTWFR[UOjIHPlcIx{KGK7IFXMTXNCNCCLQ{WwQVAvOTRizszN NVX4bmJIOjB6MUe1NlM>
CAL27 cells MU\DfZRwfG:6aXPpeJkh[XO|YYm= MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDRWwzPyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDFS2ZTKGK7IILld4F7fXKrbjDkfYUhemWmdXP0bY9vKGG|c3H5MEBKSzVyPUCuNFA4KM7:TT6= M3THXFIyODhyNkK5
SKOV3 cells NYDleJd7S3m2b4TvfIlkcXS7IHHzd4F6 MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT29XOyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISXIzKGK7IILld4F7fXKrbjDkfYUhemWmdXP0bY9vKGG|c3H5MEBKSzVyPUCuNFA{KM7:TT6= NXzkUpNGOjFyOEC2Nlk>
CAL27 cells MlH4SpVv[3Srb36gZZN{[Xl? NEjlXlIyPiCq MVfJcohq[mm2aX;uJI9nKEWJRj3pcoR2[2WmIFXHSnIheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGNCVDJ5IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJGVITlJiYX\0[ZIhOTZiaILzJIJ6KFenc4Tldo4h[myxdDygTWM2OD1yLkCzNkDPxE1? M{THZlIyODhyNkK5
SK-BR-3 cells M{\MfHBzd2yrZnXyZZRqd25iYYPzZZk> NW\4VHlWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBGemKEMjDveoVz\XiycnXzd4lv\yCqdX3hckBUUy2EUj2zJINmdGy|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlA{OiEQvF2= NEezVVYzOTV5MEi0Ny=>
BXF T24 cells NXrlZ|NVS3m2b4TvfIlkcXS7IHHzd4F6 M1TJTVQh\GG7cx?= NIftNGREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDYEZiVEK0JINmdGy|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NF06NjZ3IN88US=> MUOyNlE3QTZyMR?=
CXF 269L cells MXzDfZRwfG:6aXPpeJkh[XO|YYm= M2CwSFQh\GG7cx?= M1fScGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNZTiB{NknMJINmdGy|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NF05NjN4IN88US=> M1L2XFIzOTZ7NkCx
DIFI cells MoW1R5l1d3SxeHnjbZR6KGG|c3H5 NYnVT21IPCCmYYnz MnrTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSGlHUSClZXzsd{Bi\nSncjC0JIRigXNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdo9u\XS{aXOgZY5idHm|aYOsJGlEPTB;MD6yN|Uh|ryP NXnVZlJzOjJzNkm2NFE>
HT-29 cells M1;TfmN6fG:2b4jpZ4l1gSCjc4PhfS=> MY[0JIRigXN? NIq1e|hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUC9OE43OiEQvF2= MlfkNlIyPjl4MEG=
RKO cells M2LUV2N6fG:2b4jpZ4l1gSCjc4PhfS=> MkLMOEBl[Xm| MY\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDST28h[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTVwM{Wg{txO NXvRdVEyOjJzNkm2NFE>
GXF251L cells MkTyR5l1d3SxeHnjbZR6KGG|c3H5 MVu0JIRigXN? NUXpdXduS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hT1iIMkWxUEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:OS52ODFOwG0> MmrFNlIyPjl4MEG=
LIXF 575L cells NGfCbpBEgXSxdH;4bYNqfHliYYPzZZk> NWXX[lV[PCCmYYnz NG\uSYpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNUViIIEW3OWwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTdwMUig{txO NYPuT4lJOjJzNkm2NFE>
LXFA 289L cells NYTmemZlS3m2b4TvfIlkcXS7IHHzd4F6 MVG0JIRigXN? MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMXGZCKDJ6OVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVUvPzlizszN M2\WRlIzOTZ7NkCx
LXFA 526L NX6xT5drS3m2b4TvfIlkcXS7IHHzd4F6 NXzhblZRPCCmYYnz Ml;UR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUHhHSSB3Mk\MJINmdGy|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NF01NjJzIN88US=> MnP4NlIyPjl4MEG=
LXFA 629L cells NH7BNZpEgXSxdH;4bYNqfHliYYPzZZk> NVLqPFlSPCCmYYnz M3GwTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxZTkFiNkK5UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:Oi56NzFOwG0> Mn3kNlIyPjl4MEG=
LXFL 1121L cells MmTXR5l1d3SxeHnjbZR6KGG|c3H5 M3zpOVQh\GG7cx?= M1H5SWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxZTkxiMUGyNWwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTdwN{Og{txO M3:2[lIzOTZ7NkCx
LXFL 529L cells MUjDfZRwfG:6aXPpeJkh[XO|YYm= M1PsVVQh\GG7cx?= NIPR[o1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNYE[OIEWyPWwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTNwNUGg{txO MVGyNlE3QTZyMR?=
MCF7 cells MWXDfZRwfG:6aXPpeJkh[XO|YYm= NEnsVHQ1KGSjeYO= NHSxfZFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFQh\GG7czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIH\seY9zd22ndILpZ{BidmGueYPpd{whUUN3ME20Mlg{KM7:TR?= NGf3bXUzOjF4OU[wNS=>
MDA231 cells M4\BfWN6fG:2b4jpZ4l1gSCjc4PhfS=> Ml6xOEBl[Xm| NInFU4VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEF{M{GgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVcvPyEQvF2= Mn3ONlIyPjl4MEG=
OVXF 899L MULDfZRwfG:6aXPpeJkh[XO|YYm= MkPzOEBl[Xm| MlrHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZZTiB6OUnMJINmdGy|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NF0{NjN3IN88US=> Mm\0NlIyPjl4MEG=
PAXF 546L cells NITJSXdEgXSxdH;4bYNqfHliYYPzZZk> Mo\ROEBl[Xm| NUX4OWRTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEG[RjC1OFZNKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OD14LkGyJO69VQ>? NWXB[YxROjJzNkm2NFE>
PANC1 cells NI\vcVZEgXSxdH;4bYNqfHliYYPzZZk> NEfEcGw1KGSjeYO= NH3VXY1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSU6FMTDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUC9PE4yOiEQvF2= NFr6O2EzOjF4OU[wNS=>
22Rv1 cell NXTFU2hDS3m2b4TvfIlkcXS7IHHzd4F6 M4LlRlQh\GG7cx?= NITEb3BEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckAzOlK4MTDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUC9Ok4xPiEQvF2= MljUNlIyPjl4MEG=
DU145 cells NYHkPIdxS3m2b4TvfIlkcXS7IHHzd4F6 Mn3lOEBl[Xm| MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC0JIRigXNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdo9u\XS{aXOgZY5idHm|aYOsJGlEPTB;Mj65PUDPxE1? M1nJ[VIzOTZ7NkCx
LNCAP cells M{eybmN6fG:2b4jpZ4l1gSCjc4PhfS=> NWXy[3FJPCCmYYnz MoDDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG5ESVBiY3XscJMh[W[2ZYKgOEBl[Xm|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnz1c5JwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPUOuOlgh|ryP NF65O|MzOjF4OU[wNS=>
PC3M cells MXvDfZRwfG:6aXPpeJkh[XO|YYm= NGHndmY1KGSjeYO= NUPtbZdWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|TTDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUC9OE42PSEQvF2= MlrxNlIyPjl4MEG=
NIH/3T3 cells MnPRVJJwdGmoZYLheIlwdiCjc4PhfS=> NFPwUlU4OiCq MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKE6LSD:zWFMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD12LkOg{txO M2LtRlIzPTl3MUe3
NCI-H1648 cell Mln4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUDYbXI{UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3PDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkCyOVQ1KM7:TR?= MoTyV2FPT0WU
NMC-G1 cell NWT4W3hXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3y2VGlvcGmkaYTpc44hd2ZiaIXtZY4hVk2FLVexJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{42PDVyMTFOwG0> NX[3VnN6W0GQR1XS
NTERA-S-cl-D1 cell NVnVZlJ1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIHlVldKdmirYnn0bY9vKG:oIHj1cYFvKE6WRWLBMXMu[2xvREGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlI3PTZzIN88US=> MYfTRW5ITVJ?
OCUB-M cell NGrPVHpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkD6TY5pcWKrdHnvckBw\iCqdX3hckBQS1WELV2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA2PzRizszN MnHDV2FPT0WU
OS-RC-2 cell M17abGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHPNTpVKdmirYnn0bY9vKG:oIHj1cYFvKE:VLWLDMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjl7MUm5JO69VQ>? NVrIXFBzW0GQR1XS
OVCAR-4 cell M4L5Wmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1LpTmlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvOTF4N{Wg{txO MX7TRW5ITVJ?
RL95-2 cell M{TLfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF\E[o1KdmirYnn0bY9vKG:oIHj1cYFvKFKOOUWtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOTV4NzFOwG0> NX7h[Zl7W0GQR1XS
SW954 cell NHjr[5BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHTqPJlKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUW0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{QTJ2NTFOwG0> MlnhV2FPT0WU
SW962 cell M3S2dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnzqTY5pcWKrdHnvckBw\iCqdX3hckBUXzl4MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuN|kzPDVizszN NX3TW4tbW0GQR1XS
TE-1 cell NF3JSYdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUjJcohq[mm2aX;uJI9nKGi3bXHuJHRGNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkCyNVU6KM7:TR?= NEPwc2dUSU6JRWK=
A253 cell Mor2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEjud5NKdmirYnn0bY9vKG:oIHj1cYFvKEF{NUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlA1QDNizszN NYXvTI1NW0GQR1XS
A388 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnzqTY5pcWKrdHnvckBw\iCqdX3hckBCOzh6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6wOFg{KM7:TR?= NUi5[op6W0GQR1XS
BB30-HNC cell NF2xTGdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFXYdWpKdmirYnn0bY9vKG:oIHj1cYFvKEKEM{CtTG5EKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS57N{OzOUDPxE1? M4TxW3NCVkeHUh?=
TE-12 cell MnznS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGm0VnlKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OjJ3ODFOwG0> NUnxdYZvW0GQR1XS
TE-5 cell M4TMb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWLJcohq[mm2aX;uJI9nKGi3bXHuJHRGNTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkK0OlU1KM7:TR?= MoTjV2FPT0WU
TE-6 cell NFLLXnNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3zBdWlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFkxPTdizszN M3\NenNCVkeHUh?=
TE-8 cell NYfocZh1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NITIWpNKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlA{PzNizszN MY\TRW5ITVJ?
TE-9 cell M2rkVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnP1TY5pcWKrdHnvckBw\iCqdX3hckBVTS17IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT61OVIxOSEQvF2= MkDVV2FPT0WU
TK10 cell M2C3c2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF\ONYJKdmirYnn0bY9vKG:oIHj1cYFvKFSNMUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlE3PTJ{IN88US=> M{TGRXNCVkeHUh?=
DSH1 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEjlUJVKdmirYnn0bY9vKG:oIHj1cYFvKESVSEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA6Ozl4IN88US=> M4LwWnNCVkeHUh?=
ECC12 cell NEjZbYpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWW1[FRWUW6qaXLpeIlwdiCxZjDoeY1idiCHQ1OxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODl{M{Gg{txO M{Li[nNCVkeHUh?=
EKVX cell NF\1[YdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGfjclJKdmirYnn0bY9vKG:oIHj1cYFvKEWNVmigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ1QDd2IN88US=> NE\IPJVUSU6JRWK=
HCC2218 cell MnzkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXzJcohq[mm2aX;uJI9nKGi3bXHuJGhESzJ{MUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA2OzJ4IN88US=> MV\TRW5ITVJ?
LB2241-RCC cell M2DZc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml\zTY5pcWKrdHnvckBw\iCqdX3hckBNSjJ{NEGtVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5zNUSwN{DPxE1? MVnTRW5ITVJ?
LB996-RCC cell Mlz3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2DtZWlvcGmkaYTpc44hd2ZiaIXtZY4hVEJ7OU[tVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5|NkKyPEDPxE1? MXPTRW5ITVJ?
LC-1F cell NF;vfXNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYHJcohq[mm2aX;uJI9nKGi3bXHuJGxENTGIIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6zPFI1PCEQvF2= MmfXV2FPT0WU
LS-513 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4K2RWlvcGmkaYTpc44hd2ZiaIXtZY4hVFNvNUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{41ODB2MTFOwG0> NHHrfZJUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Lapatinib Ditosylate (~100 mg/kg) twice daily significantly inhibits the growth of BT474 and HN5 xenografts in a dose-dependent manner. [1]

Protocol

Kinase Assay:[1]
+ Expand

In vitro kinase assays:

The IC50 values for inhibition of enzyme activity are generated by measuring inhibition of phosphorylation of a peptide substrate. The intracellular kinase domains of EGFR and ErbB2 are purified from a baculovirus expression system. EGFR and ErbB2 reactions are performed in 96-well polystyrene round-bottomed plates in a final volume of 45 μL. Reaction mixtures contain 50 mM 4-morpholinepropanesulfonic acid (pH 7.5), 2 mM MnCl2, 10 μM ATP, 1 μCi of [γ33P] ATP/reaction, 50 μM Peptide A [Biotin-(amino hexonoic acid)-EEEEYFELVAKKK-CONH2], 1 mM dithiothreitol, and 1 μL of DMSO containing serial dilutions of Lapatinib beginning at 10 μM. The reaction is initiated by adding the indicated purified type-1 receptor intracellular domain. The amount of enzyme added is 1 pmol/reaction (20 nM). Reactions are terminated after 10 minutes at 23°C by adding 45 μL of 0.5% phosphoric acid in water. The terminated reaction mix (75 μL) is transferred to phosphocellulose filter plates. The plates are filtered and washed three times with 200 μL of 0.5% phosphoric acid. Scintillation cocktail (50 μL) is added to each well, and the assay is quantified by counting in a Packard Topcount. IC50 values are generated from 10-point dose-response curves.
Cell Research:[1]
+ Expand
  • Cell lines: HFF, MCF-7, T47D, A-431, HN5, BT474, N87, CaLu-3, HB4a, and HB4a c5.2
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 72 hours
  • Method: Cells are exposed to various concentrations of Lapatinib for 72 hours. Relative cell number is estimated using methylene blue staining. The absorbance at 620 nm is read in a Spectra microplate reader. Cell death and cell cycle analysis are assessed by propidium iodide staining and antibody detection of incorporated BrdUrd and staining with propidium iodide.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: CD-1 nude female mice implanted s.c. with HN5 cells, and C.B-17 SCID female mice implanted s.c. with BT474 cells
  • Formulation: Formulated in a vehicle of sulfo-butyl-ether-β-cyclodextrin 10% aqueous solution (CD10)
  • Dosages: ~100 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 925.46
Formula

C29H26ClFN4O4S.2C7H8O3S

CAS No. 388082-77-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03784014 Not yet recruiting Soft Tissue Sarcoma Institut National de la Santé Et de la Recherche Médicale France|Commissariat A L''energie Atomique|Institut Bergonié|Plateforme labellisée Inca – Institut Bergonié Bordeaux|Plateforme labellisée Inca – Hôpital Européen Georges Pompidou Paris|CIC-EC 1401/EUCLID March 2019 Phase 3
NCT03784014 Not yet recruiting Soft Tissue Sarcoma Institut National de la Santé Et de la Recherche Médicale France|Commissariat A L''energie Atomique|Institut Bergonié|Plateforme labellisée Inca – Institut Bergonié Bordeaux|Plateforme labellisée Inca – Hôpital Européen Georges Pompidou Paris|CIC-EC 1401/EUCLID March 2019 Phase 3
NCT03523585 Recruiting Breast Cancer Daiichi Sankyo Inc.|Daiichi Sankyo Co. Ltd. August 1 2018 Phase 3
NCT03523585 Recruiting Breast Cancer Daiichi Sankyo Inc.|Daiichi Sankyo Co. Ltd. August 1 2018 Phase 3
NCT03500380 Recruiting Breast Neoplasms|Breast Diseases|Capecitabine|HER2-positive Breast Cancer|HER2 Positive Breast Carcinoma RemeGen April 2018 Phase 2
NCT03500380 Recruiting Breast Neoplasms|Breast Diseases|Capecitabine|HER2-positive Breast Cancer|HER2 Positive Breast Carcinoma RemeGen April 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    If I need to use S1028 for treating tumor-bearing mice with injection, how could I prepare the solution?

  • Answer:

    S1028 Lapatinib Ditosylate can be dissolved in 2% DMSO/30% PEG 300/ddH2O at 10 mg/ml as clear solution.

HER2 Signaling Pathway Map

HER2 Inhibitors with Unique Features

Related HER2 Products4

Tags: buy Lapatinib (GW-572016) Ditosylate | Lapatinib (GW-572016) Ditosylate supplier | purchase Lapatinib (GW-572016) Ditosylate | Lapatinib (GW-572016) Ditosylate cost | Lapatinib (GW-572016) Ditosylate manufacturer | order Lapatinib (GW-572016) Ditosylate | Lapatinib (GW-572016) Ditosylate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID